PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignanciesAdi Diab, Mario Sznol, Michael E. Hurwitz et al.|Annals of Oncology|2017Cited by 5
P2.07-062 PIVOT-02: Phase 1/2 Study of NKTR-214 and Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor MalignanciesV. Papadimitrakopoulou, Adi Diab, Salah-Eddine Bentebibel et al.|Journal of Thoracic Oncology|2017Cited by 5